| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Adrenomedullin | 30 | 2023 | 80 | 8.820 |
Why?
|
| Calcitonin Gene-Related Peptide | 46 | 2021 | 86 | 8.560 |
Why?
|
| Diet, Protein-Restricted | 19 | 2024 | 82 | 8.550 |
Why?
|
| Placenta | 33 | 2022 | 542 | 5.920 |
Why?
|
| Pregnancy | 138 | 2024 | 7551 | 4.600 |
Why?
|
| Prenatal Exposure Delayed Effects | 16 | 2024 | 242 | 3.940 |
Why?
|
| Pregnancy, Animal | 22 | 2013 | 72 | 3.910 |
Why?
|
| Rats | 112 | 2024 | 3612 | 3.860 |
Why?
|
| Nitric Oxide | 38 | 2016 | 470 | 3.830 |
Why?
|
| Peptide Hormones | 13 | 2022 | 71 | 3.820 |
Why?
|
| Diabetes, Gestational | 8 | 2023 | 114 | 3.720 |
Why?
|
| Estradiol | 32 | 2020 | 488 | 3.420 |
Why?
|
| Vasodilation | 18 | 2016 | 181 | 3.410 |
Why?
|
| Rats, Sprague-Dawley | 85 | 2017 | 1225 | 3.300 |
Why?
|
| Pre-Eclampsia | 14 | 2020 | 230 | 3.280 |
Why?
|
| Mesenteric Arteries | 18 | 2015 | 51 | 3.100 |
Why?
|
| Progesterone | 31 | 2011 | 450 | 2.860 |
Why?
|
| Uterus | 34 | 2016 | 547 | 2.790 |
Why?
|
| Uterine Artery | 6 | 2022 | 29 | 2.630 |
Why?
|
| Trophoblasts | 12 | 2018 | 121 | 2.450 |
Why?
|
| Angiotensin II | 7 | 2019 | 164 | 2.310 |
Why?
|
| Receptors, Calcitonin Gene-Related Peptide | 14 | 2014 | 20 | 2.200 |
Why?
|
| Fetal Development | 9 | 2020 | 132 | 2.080 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 4 | 2022 | 46 | 2.050 |
Why?
|
| RNA, Messenger | 31 | 2023 | 2679 | 1.910 |
Why?
|
| Peptide Fragments | 19 | 2019 | 799 | 1.870 |
Why?
|
| Calcitonin Receptor-Like Protein | 14 | 2019 | 22 | 1.820 |
Why?
|
| Insulin Resistance | 8 | 2022 | 696 | 1.820 |
Why?
|
| Animals | 136 | 2024 | 34951 | 1.800 |
Why?
|
| Muscle, Smooth, Vascular | 7 | 2021 | 238 | 1.780 |
Why?
|
| Insulin | 6 | 2022 | 1167 | 1.760 |
Why?
|
| Myocytes, Smooth Muscle | 5 | 2022 | 190 | 1.760 |
Why?
|
| Glucose Intolerance | 4 | 2020 | 85 | 1.760 |
Why?
|
| Female | 165 | 2024 | 70664 | 1.740 |
Why?
|
| Maternal Nutritional Physiological Phenomena | 6 | 2017 | 50 | 1.730 |
Why?
|
| Nitric Oxide Synthase | 22 | 2011 | 173 | 1.650 |
Why?
|
| Rats, Wistar | 8 | 2024 | 329 | 1.630 |
Why?
|
| Insulin-Secreting Cells | 3 | 2022 | 146 | 1.620 |
Why?
|
| Fetal Growth Retardation | 10 | 2016 | 256 | 1.600 |
Why?
|
| Lipid Metabolism | 4 | 2020 | 382 | 1.600 |
Why?
|
| Adipose Tissue | 4 | 2022 | 511 | 1.590 |
Why?
|
| CD55 Antigens | 5 | 2014 | 10 | 1.540 |
Why?
|
| Receptors, Calcitonin | 10 | 2022 | 21 | 1.470 |
Why?
|
| Neuropeptides | 6 | 2014 | 117 | 1.370 |
Why?
|
| Peptidyl-Dipeptidase A | 4 | 2016 | 55 | 1.340 |
Why?
|
| Omentum | 4 | 2022 | 47 | 1.300 |
Why?
|
| Blood Pressure | 23 | 2020 | 1396 | 1.290 |
Why?
|
| Vasoconstriction | 6 | 2015 | 104 | 1.270 |
Why?
|
| Dietary Proteins | 5 | 2017 | 219 | 1.270 |
Why?
|
| Hypertension | 12 | 2015 | 1387 | 1.260 |
Why?
|
| Muscle, Skeletal | 5 | 2024 | 1038 | 1.250 |
Why?
|
| Testosterone | 14 | 2020 | 611 | 1.240 |
Why?
|
| Endothelium, Vascular | 12 | 2015 | 492 | 1.240 |
Why?
|
| Glucose | 7 | 2023 | 878 | 1.210 |
Why?
|
| Gonadal Steroid Hormones | 7 | 2014 | 91 | 1.110 |
Why?
|
| Receptor Activity-Modifying Protein 1 | 9 | 2022 | 13 | 1.110 |
Why?
|
| Energy Metabolism | 2 | 2024 | 784 | 1.100 |
Why?
|
| Labor, Obstetric | 15 | 2003 | 97 | 1.100 |
Why?
|
| Receptors, Adrenomedullin | 8 | 2022 | 16 | 1.040 |
Why?
|
| Uterine Contraction | 13 | 2021 | 29 | 1.040 |
Why?
|
| Arteries | 5 | 2016 | 221 | 1.030 |
Why?
|
| In Vitro Techniques | 20 | 2022 | 868 | 0.990 |
Why?
|
| Receptor Activity-Modifying Protein 2 | 6 | 2022 | 12 | 0.990 |
Why?
|
| Protein Deficiency | 3 | 2017 | 18 | 0.980 |
Why?
|
| Mitochondrial Dynamics | 2 | 2024 | 55 | 0.980 |
Why?
|
| Folic Acid | 2 | 2019 | 290 | 0.980 |
Why?
|
| NG-Nitroarginine Methyl Ester | 23 | 2011 | 59 | 0.960 |
Why?
|
| Complement Activation | 3 | 2020 | 49 | 0.950 |
Why?
|
| Fetal Macrosomia | 3 | 2022 | 20 | 0.940 |
Why?
|
| Arginine | 12 | 2017 | 341 | 0.940 |
Why?
|
| Embryo Implantation | 4 | 2015 | 229 | 0.930 |
Why?
|
| Peptides | 7 | 2006 | 846 | 0.930 |
Why?
|
| Complement C5a | 2 | 2015 | 22 | 0.920 |
Why?
|
| Receptor Activity-Modifying Protein 3 | 5 | 2022 | 12 | 0.910 |
Why?
|
| Amniotic Fluid | 2 | 2016 | 154 | 0.900 |
Why?
|
| Membrane Proteins | 15 | 2022 | 1596 | 0.890 |
Why?
|
| Pregnancy Complications | 5 | 2020 | 550 | 0.880 |
Why?
|
| Abortion, Spontaneous | 2 | 2015 | 84 | 0.860 |
Why?
|
| Vasoconstrictor Agents | 2 | 2019 | 140 | 0.820 |
Why?
|
| Mitochondria | 6 | 2023 | 752 | 0.800 |
Why?
|
| Ovariectomy | 18 | 2011 | 171 | 0.800 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2020 | 1408 | 0.780 |
Why?
|
| Cyclic GMP | 11 | 2012 | 95 | 0.780 |
Why?
|
| Gene Expression | 6 | 2020 | 1564 | 0.780 |
Why?
|
| Vasodilator Agents | 5 | 2015 | 208 | 0.760 |
Why?
|
| Cyclic AMP | 7 | 2015 | 234 | 0.760 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 13 | 2021 | 579 | 0.750 |
Why?
|
| Nitric Oxide Synthase Type III | 11 | 2016 | 190 | 0.740 |
Why?
|
| Complement C3 | 2 | 2020 | 51 | 0.740 |
Why?
|
| Receptors, Androgen | 3 | 2014 | 410 | 0.740 |
Why?
|
| Subcutaneous Fat | 1 | 2022 | 35 | 0.740 |
Why?
|
| Blotting, Western | 18 | 2017 | 1085 | 0.730 |
Why?
|
| Receptor Activity-Modifying Proteins | 12 | 2015 | 16 | 0.730 |
Why?
|
| Matrix Metalloproteinase 2 | 4 | 2016 | 91 | 0.710 |
Why?
|
| Placentation | 6 | 2019 | 60 | 0.710 |
Why?
|
| Placenta Growth Factor | 2 | 2019 | 16 | 0.690 |
Why?
|
| Vitamin B Complex | 2 | 2019 | 42 | 0.690 |
Why?
|
| Sugars | 1 | 2020 | 17 | 0.680 |
Why?
|
| Signal Transduction | 10 | 2017 | 4725 | 0.680 |
Why?
|
| Enzyme Inhibitors | 14 | 2014 | 589 | 0.680 |
Why?
|
| Receptors, Complement 3b | 1 | 2020 | 10 | 0.670 |
Why?
|
| Ovary | 5 | 2020 | 371 | 0.670 |
Why?
|
| Glucose Tolerance Test | 5 | 2020 | 207 | 0.670 |
Why?
|
| Isoenzymes | 7 | 1998 | 222 | 0.670 |
Why?
|
| Ganglia, Spinal | 6 | 2009 | 69 | 0.660 |
Why?
|
| Embryonic and Fetal Development | 5 | 2002 | 129 | 0.660 |
Why?
|
| Vesicular Transport Proteins | 1 | 2021 | 123 | 0.650 |
Why?
|
| Placental Circulation | 2 | 2013 | 25 | 0.650 |
Why?
|
| Complement System Proteins | 1 | 2020 | 59 | 0.640 |
Why?
|
| Islets of Langerhans | 2 | 2017 | 163 | 0.630 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 10 | 2017 | 1292 | 0.630 |
Why?
|
| Dose-Response Relationship, Drug | 17 | 2022 | 1672 | 0.630 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2022 | 666 | 0.610 |
Why?
|
| Escherichia coli Infections | 6 | 2011 | 192 | 0.610 |
Why?
|
| Myometrium | 8 | 2003 | 47 | 0.610 |
Why?
|
| Cell Line | 11 | 2019 | 2730 | 0.600 |
Why?
|
| Gene Expression Regulation | 12 | 2021 | 2444 | 0.590 |
Why?
|
| Complement Membrane Attack Complex | 1 | 2018 | 8 | 0.590 |
Why?
|
| Matrix Metalloproteinase 9 | 3 | 2016 | 137 | 0.590 |
Why?
|
| Endometrium | 3 | 2012 | 274 | 0.580 |
Why?
|
| Receptor, Angiotensin, Type 1 | 3 | 2014 | 50 | 0.570 |
Why?
|
| Amino Acids | 2 | 2019 | 626 | 0.570 |
Why?
|
| Hormone Antagonists | 8 | 2005 | 49 | 0.560 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2019 | 145 | 0.560 |
Why?
|
| Cell Movement | 3 | 2011 | 891 | 0.560 |
Why?
|
| Insulin Receptor Substrate Proteins | 2 | 2017 | 78 | 0.560 |
Why?
|
| Blood Glucose | 3 | 2019 | 1121 | 0.550 |
Why?
|
| Receptors, Ghrelin | 1 | 2017 | 30 | 0.540 |
Why?
|
| Ghrelin | 1 | 2017 | 56 | 0.530 |
Why?
|
| Estrus | 6 | 2008 | 13 | 0.530 |
Why?
|
| Gestational Age | 10 | 2019 | 1227 | 0.530 |
Why?
|
| Phenols | 2 | 2015 | 57 | 0.530 |
Why?
|
| Adipokines | 1 | 2017 | 72 | 0.520 |
Why?
|
| Hypoxia | 2 | 2015 | 259 | 0.520 |
Why?
|
| Oocytes | 1 | 2019 | 291 | 0.510 |
Why?
|
| Lung | 2 | 2016 | 1556 | 0.510 |
Why?
|
| Fetus | 7 | 2016 | 598 | 0.510 |
Why?
|
| Decidua | 2 | 2015 | 136 | 0.510 |
Why?
|
| Cells, Cultured | 12 | 2018 | 3061 | 0.490 |
Why?
|
| Humans | 56 | 2023 | 132083 | 0.490 |
Why?
|
| Complement C4a | 1 | 2015 | 4 | 0.490 |
Why?
|
| Complement Factor B | 1 | 2015 | 11 | 0.480 |
Why?
|
| Flutamide | 4 | 2014 | 27 | 0.480 |
Why?
|
| Bacterial Adhesion | 2 | 2014 | 106 | 0.480 |
Why?
|
| Mucin-1 | 1 | 2015 | 38 | 0.480 |
Why?
|
| Endothelin Receptor Antagonists | 1 | 2015 | 15 | 0.480 |
Why?
|
| Dyslipidemias | 1 | 2018 | 241 | 0.480 |
Why?
|
| Down-Regulation | 7 | 2014 | 679 | 0.480 |
Why?
|
| Thinness | 1 | 2016 | 74 | 0.470 |
Why?
|
| Peptides, Cyclic | 1 | 2015 | 52 | 0.470 |
Why?
|
| Estrogens, Non-Steroidal | 1 | 2015 | 17 | 0.470 |
Why?
|
| Gene Expression Regulation, Developmental | 3 | 2020 | 1019 | 0.460 |
Why?
|
| Obesity | 3 | 2022 | 2394 | 0.450 |
Why?
|
| Complement Inactivator Proteins | 1 | 2014 | 3 | 0.450 |
Why?
|
| Intra-Abdominal Fat | 3 | 2020 | 60 | 0.450 |
Why?
|
| Estrous Cycle | 1 | 2014 | 36 | 0.450 |
Why?
|
| Calcium Signaling | 2 | 2007 | 254 | 0.440 |
Why?
|
| Endocrine Disruptors | 1 | 2015 | 53 | 0.440 |
Why?
|
| Benzhydryl Compounds | 1 | 2015 | 68 | 0.440 |
Why?
|
| Sex Characteristics | 4 | 2013 | 328 | 0.430 |
Why?
|
| Ovulation | 1 | 2014 | 107 | 0.430 |
Why?
|
| Uropathogenic Escherichia coli | 1 | 2014 | 21 | 0.420 |
Why?
|
| Lipids | 3 | 2023 | 560 | 0.420 |
Why?
|
| Proto-Oncogene Proteins c-raf | 2 | 2011 | 19 | 0.420 |
Why?
|
| Maternal Exposure | 1 | 2015 | 156 | 0.410 |
Why?
|
| ELAV Proteins | 1 | 2013 | 14 | 0.400 |
Why?
|
| Insulin-Like Growth Factor II | 2 | 2012 | 40 | 0.400 |
Why?
|
| Apoptosis | 4 | 2014 | 1904 | 0.390 |
Why?
|
| Oxygen Consumption | 2 | 2024 | 304 | 0.390 |
Why?
|
| 17-Hydroxysteroid Dehydrogenases | 1 | 2012 | 7 | 0.390 |
Why?
|
| Sp1 Transcription Factor | 1 | 2013 | 42 | 0.390 |
Why?
|
| Caveolae | 1 | 2012 | 9 | 0.390 |
Why?
|
| Postpartum Period | 10 | 2006 | 231 | 0.390 |
Why?
|
| Contrast Media | 5 | 2022 | 508 | 0.390 |
Why?
|
| Androgens | 2 | 2013 | 277 | 0.390 |
Why?
|
| Adaptation, Physiological | 2 | 2013 | 274 | 0.380 |
Why?
|
| Steroids | 3 | 2003 | 173 | 0.380 |
Why?
|
| DNA, Mitochondrial | 2 | 2024 | 243 | 0.380 |
Why?
|
| Testosterone Propionate | 2 | 2013 | 3 | 0.380 |
Why?
|
| Receptors, Angiotensin | 1 | 2012 | 20 | 0.380 |
Why?
|
| Phosphorylation | 6 | 2017 | 1613 | 0.370 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2012 | 246 | 0.370 |
Why?
|
| Sex Factors | 6 | 2017 | 1349 | 0.360 |
Why?
|
| Amino Acid Transport Systems | 1 | 2011 | 10 | 0.360 |
Why?
|
| Up-Regulation | 8 | 2018 | 880 | 0.360 |
Why?
|
| HLA-G Antigens | 1 | 2011 | 13 | 0.360 |
Why?
|
| Receptor, Nerve Growth Factor | 2 | 2001 | 8 | 0.360 |
Why?
|
| Receptor, Angiotensin, Type 2 | 1 | 2012 | 39 | 0.360 |
Why?
|
| Aging | 4 | 2009 | 1253 | 0.360 |
Why?
|
| Birth Weight | 6 | 2011 | 351 | 0.360 |
Why?
|
| Inflammation | 2 | 2018 | 1521 | 0.350 |
Why?
|
| Epithelial Cells | 2 | 2014 | 903 | 0.350 |
Why?
|
| Immunohistochemistry | 9 | 2017 | 1722 | 0.350 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2020 | 2851 | 0.340 |
Why?
|
| MAP Kinase Signaling System | 2 | 2014 | 309 | 0.340 |
Why?
|
| Calcium | 4 | 2014 | 1083 | 0.340 |
Why?
|
| Male | 29 | 2024 | 64904 | 0.330 |
Why?
|
| Cell Differentiation | 3 | 2014 | 1975 | 0.330 |
Why?
|
| Uterine Diseases | 4 | 2011 | 22 | 0.330 |
Why?
|
| Dinoprost | 3 | 1999 | 24 | 0.330 |
Why?
|
| Muscle Contraction | 2 | 2010 | 154 | 0.330 |
Why?
|
| Gadolinium | 4 | 2019 | 116 | 0.320 |
Why?
|
| Cytosol | 3 | 2014 | 144 | 0.310 |
Why?
|
| Mice, Inbred C57BL | 6 | 2021 | 4764 | 0.310 |
Why?
|
| 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid | 2 | 2022 | 33 | 0.310 |
Why?
|
| Lipolysis | 2 | 2020 | 75 | 0.310 |
Why?
|
| Reference Values | 5 | 2017 | 704 | 0.310 |
Why?
|
| Adipocytes | 2 | 2023 | 182 | 0.310 |
Why?
|
| Stem Cells | 1 | 2014 | 732 | 0.310 |
Why?
|
| Umbilical Veins | 2 | 2007 | 70 | 0.300 |
Why?
|
| Models, Animal | 4 | 2019 | 470 | 0.300 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 3 | 1998 | 66 | 0.300 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 2 | 2007 | 160 | 0.300 |
Why?
|
| 1-Phosphatidylinositol 4-Kinase | 1 | 2008 | 9 | 0.290 |
Why?
|
| Endothelial Cells | 2 | 2009 | 530 | 0.290 |
Why?
|
| Escherichia coli | 5 | 2013 | 995 | 0.290 |
Why?
|
| Calcium Chloride | 2 | 2007 | 23 | 0.290 |
Why?
|
| Receptors, Peptide | 3 | 2005 | 54 | 0.290 |
Why?
|
| Hormones | 1 | 2009 | 170 | 0.280 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2017 | 503 | 0.280 |
Why?
|
| Receptors, G-Protein-Coupled | 2 | 2007 | 303 | 0.280 |
Why?
|
| Diet, High-Fat | 2 | 2020 | 255 | 0.280 |
Why?
|
| Adult | 13 | 2020 | 31544 | 0.280 |
Why?
|
| Case-Control Studies | 4 | 2017 | 3417 | 0.280 |
Why?
|
| Mifepristone | 6 | 2003 | 99 | 0.280 |
Why?
|
| Membrane Microdomains | 1 | 2008 | 61 | 0.280 |
Why?
|
| Membrane Cofactor Protein | 2 | 2020 | 10 | 0.280 |
Why?
|
| Mice | 15 | 2022 | 18565 | 0.280 |
Why?
|
| Nitric Oxide Synthase Type II | 6 | 2006 | 92 | 0.270 |
Why?
|
| Streptococcus agalactiae | 1 | 2008 | 103 | 0.270 |
Why?
|
| Real-Time Polymerase Chain Reaction | 3 | 2016 | 541 | 0.270 |
Why?
|
| Chorionic Villi | 3 | 2015 | 22 | 0.270 |
Why?
|
| Glucose Transporter Type 4 | 2 | 2019 | 20 | 0.260 |
Why?
|
| Vasomotor System | 2 | 2004 | 21 | 0.260 |
Why?
|
| Receptor, Insulin | 2 | 2019 | 68 | 0.260 |
Why?
|
| Obstetric Labor, Premature | 2 | 1997 | 84 | 0.250 |
Why?
|
| Potassium Channels, Calcium-Activated | 1 | 2006 | 13 | 0.250 |
Why?
|
| Mesenteric Artery, Superior | 1 | 2006 | 33 | 0.240 |
Why?
|
| Organ Size | 5 | 2012 | 447 | 0.240 |
Why?
|
| Pregnancy Trimester, First | 4 | 2015 | 124 | 0.240 |
Why?
|
| Parathyroid Hormone-Related Protein | 1 | 2005 | 10 | 0.240 |
Why?
|
| Fetal Blood | 1 | 2006 | 174 | 0.240 |
Why?
|
| Fetal Death | 3 | 2002 | 119 | 0.240 |
Why?
|
| Neovascularization, Physiologic | 1 | 2007 | 215 | 0.240 |
Why?
|
| Pregnancy Complications, Infectious | 3 | 2011 | 496 | 0.230 |
Why?
|
| Aorta | 2 | 2011 | 554 | 0.230 |
Why?
|
| Nitroglycerin | 4 | 2000 | 23 | 0.230 |
Why?
|
| Kinetics | 5 | 2019 | 1132 | 0.220 |
Why?
|
| Mitochondria, Muscle | 1 | 2024 | 38 | 0.220 |
Why?
|
| Antihypertensive Agents | 2 | 2005 | 422 | 0.220 |
Why?
|
| Glyburide | 2 | 2017 | 23 | 0.220 |
Why?
|
| Microscopy, Electron, Transmission | 2 | 2019 | 138 | 0.220 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2022 | 3854 | 0.220 |
Why?
|
| Fimbriae, Bacterial | 1 | 2004 | 44 | 0.220 |
Why?
|
| Nanoparticles | 3 | 2022 | 288 | 0.210 |
Why?
|
| Estrogen Replacement Therapy | 2 | 2011 | 50 | 0.210 |
Why?
|
| Nitrites | 5 | 2011 | 49 | 0.210 |
Why?
|
| Hyperalgesia | 3 | 2010 | 26 | 0.210 |
Why?
|
| Potassium Channel Blockers | 3 | 2010 | 84 | 0.210 |
Why?
|
| Cytochromes b | 1 | 2023 | 6 | 0.210 |
Why?
|
| Homeostasis | 2 | 2017 | 723 | 0.200 |
Why?
|
| Androgen Antagonists | 2 | 2014 | 133 | 0.200 |
Why?
|
| Losartan | 2 | 2014 | 35 | 0.200 |
Why?
|
| Fluorescent Antibody Technique | 6 | 2006 | 425 | 0.200 |
Why?
|
| Mitochondrial Proteins | 1 | 2024 | 259 | 0.200 |
Why?
|
| Cervix Uteri | 3 | 2001 | 64 | 0.200 |
Why?
|
| Organ Culture Techniques | 4 | 2007 | 157 | 0.200 |
Why?
|
| Fetal Weight | 4 | 2004 | 72 | 0.190 |
Why?
|
| Insulin, Regular, Human | 1 | 2022 | 12 | 0.190 |
Why?
|
| Kidney | 4 | 2016 | 1332 | 0.190 |
Why?
|
| Growth Hormone | 2 | 1993 | 129 | 0.190 |
Why?
|
| Apamin | 1 | 2022 | 4 | 0.190 |
Why?
|
| Charybdotoxin | 1 | 2022 | 8 | 0.190 |
Why?
|
| Arterial Pressure | 2 | 2013 | 127 | 0.190 |
Why?
|
| Bradykinin | 2 | 2016 | 50 | 0.190 |
Why?
|
| Enzyme Activation | 3 | 2011 | 618 | 0.180 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2014 | 365 | 0.180 |
Why?
|
| Renin-Angiotensin System | 2 | 2013 | 110 | 0.180 |
Why?
|
| Nerve Growth Factor | 1 | 2001 | 25 | 0.180 |
Why?
|
| Dimerization | 1 | 2022 | 149 | 0.180 |
Why?
|
| Interleukin-1 | 3 | 1997 | 137 | 0.180 |
Why?
|
| Estrogen Receptor alpha | 3 | 2012 | 439 | 0.180 |
Why?
|
| Cytochromes c | 3 | 2006 | 53 | 0.180 |
Why?
|
| Hepatocytes | 1 | 2023 | 240 | 0.180 |
Why?
|
| Animals, Newborn | 2 | 2021 | 1034 | 0.180 |
Why?
|
| Receptors, Oxytocin | 1 | 2021 | 21 | 0.170 |
Why?
|
| Osmolar Concentration | 3 | 2006 | 158 | 0.170 |
Why?
|
| TRPC Cation Channels | 1 | 2021 | 20 | 0.170 |
Why?
|
| Receptors, Progesterone | 2 | 2021 | 681 | 0.170 |
Why?
|
| Radioimmunoassay | 5 | 2007 | 99 | 0.170 |
Why?
|
| Adhesins, Escherichia coli | 2 | 2014 | 21 | 0.170 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 3 | 2006 | 180 | 0.170 |
Why?
|
| Complement Inactivating Agents | 1 | 2020 | 12 | 0.170 |
Why?
|
| Biological Factors | 3 | 2015 | 27 | 0.170 |
Why?
|
| Receptors, Complement | 1 | 2020 | 32 | 0.170 |
Why?
|
| Receptors, Prostaglandin E | 1 | 2000 | 8 | 0.160 |
Why?
|
| Receptors, Prostaglandin | 1 | 2000 | 14 | 0.160 |
Why?
|
| Testis | 2 | 2020 | 423 | 0.160 |
Why?
|
| Multigene Family | 1 | 2021 | 305 | 0.160 |
Why?
|
| Biomarkers | 4 | 2014 | 3377 | 0.160 |
Why?
|
| Complement Pathway, Alternative | 1 | 2020 | 14 | 0.160 |
Why?
|
| Calcitonin | 1 | 2000 | 32 | 0.160 |
Why?
|
| Hemodynamics | 2 | 2001 | 864 | 0.160 |
Why?
|
| Tissue Distribution | 3 | 2006 | 383 | 0.160 |
Why?
|
| Guanylate Cyclase | 3 | 2007 | 35 | 0.160 |
Why?
|
| Fertility | 1 | 2002 | 260 | 0.160 |
Why?
|
| Perilipin-1 | 1 | 2019 | 7 | 0.160 |
Why?
|
| Phosphoenolpyruvate Carboxykinase (GTP) | 1 | 2019 | 9 | 0.160 |
Why?
|
| Dietary Sugars | 1 | 2019 | 16 | 0.150 |
Why?
|
| Pyelonephritis | 1 | 1999 | 29 | 0.150 |
Why?
|
| Pregnancy Complications, Cardiovascular | 2 | 1997 | 106 | 0.150 |
Why?
|
| Follicular Phase | 1 | 2019 | 15 | 0.150 |
Why?
|
| Cumulus Cells | 1 | 2019 | 44 | 0.150 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2019 | 153 | 0.150 |
Why?
|
| Protein Phosphatase 1 | 2 | 2010 | 54 | 0.150 |
Why?
|
| Bronchopulmonary Dysplasia | 1 | 2021 | 207 | 0.150 |
Why?
|
| Litter Size | 3 | 2003 | 24 | 0.150 |
Why?
|
| Potassium Chloride | 2 | 2017 | 48 | 0.140 |
Why?
|
| Peroxidases | 1 | 1998 | 29 | 0.140 |
Why?
|
| Gene Frequency | 1 | 2020 | 750 | 0.140 |
Why?
|
| RNA, Small Interfering | 1 | 2020 | 691 | 0.140 |
Why?
|
| Nitric Oxide Donors | 2 | 2013 | 20 | 0.140 |
Why?
|
| Polyamines | 4 | 1999 | 31 | 0.140 |
Why?
|
| Disease Models, Animal | 9 | 2022 | 4694 | 0.140 |
Why?
|
| Bone Density | 3 | 2000 | 369 | 0.140 |
Why?
|
| DNA Primers | 2 | 2013 | 637 | 0.140 |
Why?
|
| Gonanes | 2 | 1997 | 13 | 0.140 |
Why?
|
| Regional Blood Flow | 2 | 2012 | 214 | 0.130 |
Why?
|
| Pregnancy Trimester, Third | 1 | 2017 | 124 | 0.130 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2017 | 62 | 0.130 |
Why?
|
| Biopsy, Needle | 1 | 2017 | 234 | 0.130 |
Why?
|
| Thapsigargin | 2 | 2007 | 23 | 0.130 |
Why?
|
| Urinary Tract Infections | 1 | 2001 | 317 | 0.130 |
Why?
|
| Somatomedins | 2 | 1994 | 34 | 0.130 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 1997 | 77 | 0.130 |
Why?
|
| Luteinizing Hormone | 1 | 1997 | 136 | 0.130 |
Why?
|
| Pituitary Gland | 1 | 1997 | 81 | 0.130 |
Why?
|
| Echo-Planar Imaging | 1 | 2016 | 23 | 0.120 |
Why?
|
| Caspase 8 | 2 | 2006 | 25 | 0.120 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 1996 | 31 | 0.120 |
Why?
|
| Hypertension, Pregnancy-Induced | 2 | 2014 | 77 | 0.120 |
Why?
|
| Pregnancy Trimester, Second | 1 | 2016 | 170 | 0.120 |
Why?
|
| Body Fat Distribution | 1 | 2016 | 32 | 0.120 |
Why?
|
| Adenylyl Cyclase Inhibitors | 2 | 2007 | 7 | 0.120 |
Why?
|
| Dinoprostone | 1 | 1996 | 70 | 0.120 |
Why?
|
| Homeodomain Proteins | 1 | 2019 | 573 | 0.120 |
Why?
|
| Enalapril | 1 | 2015 | 14 | 0.120 |
Why?
|
| Adenosine Triphosphate | 2 | 2013 | 275 | 0.120 |
Why?
|
| Trigeminal Ganglion | 4 | 2010 | 6 | 0.120 |
Why?
|
| Trans-Activators | 1 | 2019 | 714 | 0.120 |
Why?
|
| Protein Binding | 2 | 2013 | 1735 | 0.120 |
Why?
|
| Protein Kinase C-delta | 1 | 2014 | 16 | 0.110 |
Why?
|
| Cell Proliferation | 3 | 2014 | 2512 | 0.110 |
Why?
|
| Endothelins | 1 | 1994 | 8 | 0.110 |
Why?
|
| Corpus Luteum | 1 | 2014 | 25 | 0.110 |
Why?
|
| Myositis | 2 | 2006 | 105 | 0.110 |
Why?
|
| Receptors, Endothelin | 1 | 1994 | 10 | 0.110 |
Why?
|
| Lipopolysaccharides | 3 | 2021 | 306 | 0.110 |
Why?
|
| Antigens, Differentiation | 1 | 2014 | 67 | 0.110 |
Why?
|
| Simvastatin | 1 | 2014 | 77 | 0.110 |
Why?
|
| Cell Size | 1 | 2014 | 86 | 0.110 |
Why?
|
| In Situ Hybridization | 3 | 2007 | 470 | 0.110 |
Why?
|
| 3-Phosphoinositide-Dependent Protein Kinases | 1 | 2014 | 18 | 0.110 |
Why?
|
| Caspases | 2 | 2005 | 166 | 0.110 |
Why?
|
| Time Factors | 5 | 2011 | 6445 | 0.110 |
Why?
|
| Cleavage Stage, Ovum | 1 | 1993 | 4 | 0.110 |
Why?
|
| Blastomeres | 1 | 1993 | 6 | 0.110 |
Why?
|
| Drug Interactions | 3 | 2002 | 245 | 0.110 |
Why?
|
| Small-Conductance Calcium-Activated Potassium Channels | 1 | 2013 | 13 | 0.110 |
Why?
|
| Granulosa Cells | 1 | 2014 | 140 | 0.100 |
Why?
|
| GTPase-Activating Proteins | 1 | 2014 | 92 | 0.100 |
Why?
|
| Pregnancy Proteins | 2 | 2011 | 15 | 0.100 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2015 | 218 | 0.100 |
Why?
|
| Liposomes | 3 | 2019 | 203 | 0.100 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 1992 | 323 | 0.100 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2013 | 101 | 0.100 |
Why?
|
| Nitroso Compounds | 1 | 2013 | 7 | 0.100 |
Why?
|
| Fimbriae Proteins | 1 | 2013 | 22 | 0.100 |
Why?
|
| Renin | 1 | 2013 | 94 | 0.100 |
Why?
|
| Binding Sites | 2 | 2013 | 1256 | 0.100 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 399 | 0.100 |
Why?
|
| Caveolin 1 | 1 | 2012 | 50 | 0.100 |
Why?
|
| Protein Structure, Tertiary | 2 | 2005 | 764 | 0.100 |
Why?
|
| Immunoprecipitation | 1 | 2013 | 197 | 0.100 |
Why?
|
| Ethanol | 1 | 2013 | 168 | 0.100 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2013 | 148 | 0.100 |
Why?
|
| Endosomes | 1 | 2012 | 66 | 0.090 |
Why?
|
| Systole | 2 | 2003 | 203 | 0.090 |
Why?
|
| 3' Untranslated Regions | 1 | 2013 | 160 | 0.090 |
Why?
|
| Angiotensin I | 1 | 2012 | 5 | 0.090 |
Why?
|
| Cysteine | 1 | 2013 | 142 | 0.090 |
Why?
|
| Transcription, Genetic | 2 | 2011 | 1425 | 0.090 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2012 | 57 | 0.090 |
Why?
|
| Amino Acid Transport System A | 1 | 2011 | 7 | 0.090 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2014 | 446 | 0.090 |
Why?
|
| Estrogen Receptor beta | 1 | 2012 | 78 | 0.090 |
Why?
|
| Thyroxine | 1 | 1992 | 65 | 0.090 |
Why?
|
| Autocrine Communication | 1 | 2011 | 29 | 0.090 |
Why?
|
| Receptors, Nerve Growth Factor | 2 | 2001 | 17 | 0.090 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2011 | 444 | 0.090 |
Why?
|
| Weight Gain | 1 | 2014 | 379 | 0.090 |
Why?
|
| Estrogen Antagonists | 2 | 2003 | 97 | 0.090 |
Why?
|
| Receptor, trkA | 2 | 2001 | 17 | 0.090 |
Why?
|
| Fetal Mortality | 1 | 2011 | 7 | 0.090 |
Why?
|
| Umbilical Cord | 2 | 2013 | 59 | 0.090 |
Why?
|
| Paracrine Communication | 1 | 2011 | 70 | 0.090 |
Why?
|
| Corticosterone | 1 | 2011 | 60 | 0.090 |
Why?
|
| Heart Rate | 2 | 2006 | 587 | 0.090 |
Why?
|
| Vascular Resistance | 2 | 2002 | 195 | 0.090 |
Why?
|
| Carrier Proteins | 2 | 1994 | 1050 | 0.090 |
Why?
|
| Age Factors | 1 | 2017 | 2922 | 0.090 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2006 | 773 | 0.090 |
Why?
|
| Delivery, Obstetric | 1 | 1993 | 260 | 0.090 |
Why?
|
| Body Size | 1 | 2011 | 68 | 0.080 |
Why?
|
| Random Allocation | 1 | 2011 | 432 | 0.080 |
Why?
|
| Maternal Mortality | 1 | 2011 | 81 | 0.080 |
Why?
|
| Receptors, Purinergic P2 | 1 | 2010 | 17 | 0.080 |
Why?
|
| Phorbol 12,13-Dibutyrate | 1 | 2010 | 8 | 0.080 |
Why?
|
| Myosin Light Chains | 1 | 2010 | 16 | 0.080 |
Why?
|
| Phenylephrine | 1 | 2010 | 40 | 0.080 |
Why?
|
| Base Sequence | 3 | 2004 | 2902 | 0.080 |
Why?
|
| Muscle, Smooth | 2 | 2004 | 131 | 0.080 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2010 | 92 | 0.080 |
Why?
|
| Nitroprusside | 3 | 2014 | 37 | 0.080 |
Why?
|
| Keratin-7 | 1 | 2009 | 8 | 0.080 |
Why?
|
| Organ Specificity | 2 | 2002 | 413 | 0.080 |
Why?
|
| Polyunsaturated Alkamides | 2 | 2000 | 25 | 0.080 |
Why?
|
| Virulence Factors | 1 | 2011 | 187 | 0.080 |
Why?
|
| Pregnancy Trimesters | 1 | 2009 | 34 | 0.080 |
Why?
|
| Enzyme Induction | 2 | 2001 | 97 | 0.080 |
Why?
|
| Culture Techniques | 2 | 2003 | 75 | 0.080 |
Why?
|
| Antigens, CD34 | 1 | 2009 | 109 | 0.080 |
Why?
|
| Aminoquinolines | 2 | 1999 | 34 | 0.080 |
Why?
|
| Muscular Diseases | 1 | 2010 | 117 | 0.080 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 5399 | 0.080 |
Why?
|
| Promoter Regions, Genetic | 1 | 2013 | 1294 | 0.070 |
Why?
|
| Killer Cells, Natural | 1 | 2011 | 351 | 0.070 |
Why?
|
| Prognosis | 1 | 2018 | 5006 | 0.070 |
Why?
|
| Cell Line, Tumor | 2 | 2014 | 3698 | 0.070 |
Why?
|
| Drug Combinations | 2 | 2003 | 281 | 0.070 |
Why?
|
| Indoles | 1 | 2010 | 201 | 0.070 |
Why?
|
| beta-Cyclodextrins | 1 | 2008 | 12 | 0.070 |
Why?
|
| Penicillin-Binding Proteins | 1 | 2008 | 14 | 0.070 |
Why?
|
| Chromones | 1 | 2008 | 26 | 0.070 |
Why?
|
| Bacterial Capsules | 1 | 2008 | 41 | 0.070 |
Why?
|
| Androstadienes | 1 | 2008 | 52 | 0.070 |
Why?
|
| Morpholines | 1 | 2008 | 67 | 0.070 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2008 | 136 | 0.070 |
Why?
|
| Marine Toxins | 1 | 2007 | 6 | 0.070 |
Why?
|
| Sodium Fluoride | 1 | 2007 | 8 | 0.070 |
Why?
|
| Myosin-Light-Chain Phosphatase | 1 | 2007 | 5 | 0.070 |
Why?
|
| Multivariate Analysis | 1 | 2011 | 1443 | 0.070 |
Why?
|
| Immunoblotting | 1 | 2008 | 304 | 0.070 |
Why?
|
| Oxazoles | 1 | 2007 | 22 | 0.070 |
Why?
|
| Facial Pain | 1 | 2007 | 8 | 0.070 |
Why?
|
| Facial Muscles | 1 | 2007 | 25 | 0.070 |
Why?
|
| Cell Membrane | 2 | 2004 | 473 | 0.070 |
Why?
|
| Calcium-Transporting ATPases | 1 | 2007 | 41 | 0.070 |
Why?
|
| Cyclooxygenase 1 | 2 | 1998 | 27 | 0.070 |
Why?
|
| Adenylyl Cyclases | 1 | 2007 | 67 | 0.070 |
Why?
|
| Models, Biological | 1 | 2012 | 1441 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 2 | 2004 | 1038 | 0.070 |
Why?
|
| Pilot Projects | 1 | 2011 | 1452 | 0.070 |
Why?
|
| Cyclooxygenase 2 | 2 | 1998 | 127 | 0.070 |
Why?
|
| Caspase 10 | 1 | 2006 | 3 | 0.060 |
Why?
|
| Adenine | 1 | 2007 | 119 | 0.060 |
Why?
|
| Capillaries | 1 | 2007 | 71 | 0.060 |
Why?
|
| Endothelium | 2 | 1997 | 67 | 0.060 |
Why?
|
| Potassium | 1 | 2007 | 272 | 0.060 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2006 | 124 | 0.060 |
Why?
|
| Membrane Potentials | 1 | 2007 | 302 | 0.060 |
Why?
|
| Glutathione Transferase | 2 | 1997 | 142 | 0.060 |
Why?
|
| Caspase 3 | 1 | 2006 | 141 | 0.060 |
Why?
|
| Transfection | 1 | 2008 | 999 | 0.060 |
Why?
|
| Veins | 1 | 2006 | 101 | 0.060 |
Why?
|
| Molecular Weight | 2 | 2005 | 309 | 0.060 |
Why?
|
| Infant, Newborn | 2 | 2011 | 8539 | 0.060 |
Why?
|
| Drug Synergism | 2 | 1996 | 234 | 0.060 |
Why?
|
| Blastocyst | 2 | 2013 | 79 | 0.060 |
Why?
|
| Extracellular Fluid | 1 | 2005 | 13 | 0.060 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2005 | 26 | 0.060 |
Why?
|
| bcl-2 Homologous Antagonist-Killer Protein | 1 | 2005 | 14 | 0.060 |
Why?
|
| Streptococcal Infections | 1 | 2008 | 248 | 0.060 |
Why?
|
| Young Adult | 1 | 2020 | 9935 | 0.060 |
Why?
|
| Intracellular Membranes | 1 | 2005 | 59 | 0.060 |
Why?
|
| Microscopy, Confocal | 1 | 2007 | 368 | 0.060 |
Why?
|
| CARD Signaling Adaptor Proteins | 1 | 2005 | 42 | 0.060 |
Why?
|
| Cholesterol | 1 | 2008 | 559 | 0.060 |
Why?
|
| Ultracentrifugation | 1 | 2005 | 21 | 0.060 |
Why?
|
| Blood Vessels | 1 | 2005 | 106 | 0.060 |
Why?
|
| Circular Dichroism | 1 | 2005 | 80 | 0.060 |
Why?
|
| Estrogens | 2 | 1998 | 435 | 0.060 |
Why?
|
| Binding, Competitive | 1 | 2005 | 161 | 0.060 |
Why?
|
| Benzenesulfonates | 1 | 2004 | 12 | 0.060 |
Why?
|
| Iodine Radioisotopes | 1 | 2005 | 75 | 0.060 |
Why?
|
| Fetal Resorption | 1 | 2004 | 9 | 0.060 |
Why?
|
| Substance P | 2 | 2005 | 37 | 0.060 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2005 | 169 | 0.060 |
Why?
|
| Fas Ligand Protein | 1 | 2004 | 37 | 0.050 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2004 | 276 | 0.050 |
Why?
|
| fas Receptor | 1 | 2004 | 47 | 0.050 |
Why?
|
| Drug Therapy, Combination | 2 | 1998 | 1176 | 0.050 |
Why?
|
| Neurons, Afferent | 3 | 2010 | 47 | 0.050 |
Why?
|
| Ornithine Decarboxylase Inhibitors | 1 | 2003 | 10 | 0.050 |
Why?
|
| Muscle Relaxation | 1 | 2003 | 14 | 0.050 |
Why?
|
| Cloning, Molecular | 1 | 2005 | 813 | 0.050 |
Why?
|
| Retrospective Studies | 2 | 2022 | 17367 | 0.050 |
Why?
|
| Estrogen Receptor Modulators | 1 | 2003 | 39 | 0.050 |
Why?
|
| Potassium Channels | 1 | 2004 | 162 | 0.050 |
Why?
|
| Acetylcholine | 2 | 2014 | 84 | 0.050 |
Why?
|
| Ligands | 1 | 2005 | 495 | 0.050 |
Why?
|
| Treatment Outcome | 2 | 2017 | 13014 | 0.050 |
Why?
|
| Severity of Illness Index | 1 | 2011 | 3083 | 0.050 |
Why?
|
| Protein Subunits | 1 | 2003 | 171 | 0.050 |
Why?
|
| Hypophysectomy | 2 | 1993 | 20 | 0.050 |
Why?
|
| Protein Isoforms | 1 | 2003 | 422 | 0.050 |
Why?
|
| Antibody Specificity | 1 | 2003 | 201 | 0.050 |
Why?
|
| Antibodies | 1 | 2004 | 367 | 0.050 |
Why?
|
| Amnion | 1 | 2002 | 40 | 0.050 |
Why?
|
| Cross Reactions | 1 | 2003 | 190 | 0.050 |
Why?
|
| Membrane Glycoproteins | 1 | 2004 | 421 | 0.050 |
Why?
|
| Necrosis | 1 | 2002 | 210 | 0.050 |
Why?
|
| Electric Stimulation | 1 | 2002 | 251 | 0.050 |
Why?
|
| Hydrops Fetalis | 1 | 2002 | 85 | 0.050 |
Why?
|
| Growth | 1 | 2002 | 96 | 0.040 |
Why?
|
| Mice, 129 Strain | 1 | 2021 | 99 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2003 | 547 | 0.040 |
Why?
|
| Microspheres | 1 | 2001 | 74 | 0.040 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2006 | 608 | 0.040 |
Why?
|
| Immunoassay | 1 | 2001 | 135 | 0.040 |
Why?
|
| Species Specificity | 2 | 1999 | 544 | 0.040 |
Why?
|
| Injections, Intraperitoneal | 2 | 1997 | 69 | 0.040 |
Why?
|
| Cardiac Output | 1 | 2001 | 166 | 0.040 |
Why?
|
| Angiopoietin-like Proteins | 1 | 2020 | 13 | 0.040 |
Why?
|
| Parturition | 1 | 2021 | 66 | 0.040 |
Why?
|
| Colonic Neoplasms | 2 | 1994 | 264 | 0.040 |
Why?
|
| Receptors, Prostaglandin E, EP2 Subtype | 1 | 2000 | 8 | 0.040 |
Why?
|
| Mice, Mutant Strains | 1 | 2021 | 378 | 0.040 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2020 | 33 | 0.040 |
Why?
|
| Nerve Growth Factors | 1 | 2000 | 73 | 0.040 |
Why?
|
| Gene Dosage | 1 | 2021 | 449 | 0.040 |
Why?
|
| Blotting, Northern | 1 | 2000 | 253 | 0.040 |
Why?
|
| Blood Flow Velocity | 1 | 2001 | 443 | 0.040 |
Why?
|
| Behavior, Animal | 3 | 2007 | 506 | 0.040 |
Why?
|
| Blood Volume | 1 | 2019 | 81 | 0.040 |
Why?
|
| Receptors, Estrogen | 1 | 2003 | 741 | 0.040 |
Why?
|
| Mice, Inbred C3H | 1 | 1999 | 118 | 0.040 |
Why?
|
| Colony Count, Microbial | 1 | 1999 | 87 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 1 | 2003 | 1554 | 0.040 |
Why?
|
| Absorptiometry, Photon | 2 | 1997 | 204 | 0.040 |
Why?
|
| Single-Blind Method | 1 | 1999 | 242 | 0.040 |
Why?
|
| Mutation | 1 | 2013 | 6248 | 0.040 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2022 | 623 | 0.040 |
Why?
|
| Mutagenesis | 1 | 2000 | 347 | 0.040 |
Why?
|
| Cell Survival | 2 | 2014 | 869 | 0.040 |
Why?
|
| Depression, Chemical | 1 | 1998 | 37 | 0.040 |
Why?
|
| Colon | 1 | 2001 | 370 | 0.040 |
Why?
|
| Embryo Transfer | 1 | 1998 | 58 | 0.030 |
Why?
|
| Bone and Bones | 1 | 2000 | 301 | 0.030 |
Why?
|
| Hysterectomy | 1 | 1999 | 201 | 0.030 |
Why?
|
| Bone Resorption | 1 | 1997 | 52 | 0.030 |
Why?
|
| omega-N-Methylarginine | 1 | 1997 | 11 | 0.030 |
Why?
|
| RNA, Ribosomal, 18S | 1 | 1997 | 19 | 0.030 |
Why?
|
| Analysis of Variance | 2 | 1996 | 1008 | 0.030 |
Why?
|
| Masseter Muscle | 2 | 2007 | 6 | 0.030 |
Why?
|
| Intestines | 1 | 2001 | 606 | 0.030 |
Why?
|
| Puerperal Disorders | 1 | 1997 | 47 | 0.030 |
Why?
|
| Body Weight | 3 | 2000 | 993 | 0.030 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 2 | 1994 | 33 | 0.030 |
Why?
|
| Fertilization in Vitro | 1 | 1998 | 163 | 0.030 |
Why?
|
| Proestrus | 1 | 1996 | 1 | 0.030 |
Why?
|
| Gene Deletion | 1 | 2000 | 795 | 0.030 |
Why?
|
| Meglumine | 1 | 2016 | 16 | 0.030 |
Why?
|
| Infusion Pumps, Implantable | 1 | 1996 | 39 | 0.030 |
Why?
|
| RNA | 1 | 2000 | 549 | 0.030 |
Why?
|
| Injections, Subcutaneous | 1 | 1996 | 126 | 0.030 |
Why?
|
| Cesarean Section | 1 | 1999 | 407 | 0.030 |
Why?
|
| Indomethacin | 1 | 1996 | 82 | 0.030 |
Why?
|
| Fallopian Tubes | 1 | 1996 | 77 | 0.030 |
Why?
|
| T-Lymphocyte Subsets | 1 | 1997 | 210 | 0.030 |
Why?
|
| Organometallic Compounds | 1 | 2016 | 111 | 0.030 |
Why?
|
| Promegestone | 1 | 1995 | 22 | 0.030 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2016 | 85 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2021 | 2453 | 0.030 |
Why?
|
| Middle Aged | 1 | 2015 | 28922 | 0.030 |
Why?
|
| Egtazic Acid | 1 | 2014 | 19 | 0.030 |
Why?
|
| Gap Junctions | 1 | 1995 | 45 | 0.030 |
Why?
|
| Vagina | 1 | 1996 | 206 | 0.030 |
Why?
|
| Hyperandrogenism | 1 | 2014 | 25 | 0.030 |
Why?
|
| Chelating Agents | 1 | 2014 | 46 | 0.030 |
Why?
|
| Calcium Channels, L-Type | 1 | 2014 | 52 | 0.030 |
Why?
|
| Transcriptome | 1 | 2021 | 1123 | 0.030 |
Why?
|
| Amino Acid Oxidoreductases | 1 | 1994 | 10 | 0.030 |
Why?
|
| Glutathione Disulfide | 1 | 2013 | 20 | 0.030 |
Why?
|
| Methylene Blue | 1 | 1994 | 16 | 0.030 |
Why?
|
| Binge Drinking | 1 | 2013 | 10 | 0.030 |
Why?
|
| NADP | 1 | 1994 | 54 | 0.030 |
Why?
|
| Intermediate-Conductance Calcium-Activated Potassium Channels | 1 | 2013 | 15 | 0.030 |
Why?
|
| Leiomyoma | 1 | 2014 | 83 | 0.030 |
Why?
|
| Nitrates | 1 | 1993 | 33 | 0.030 |
Why?
|
| Temperature | 1 | 1994 | 305 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2016 | 1051 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2014 | 200 | 0.030 |
Why?
|
| Mice, Inbred Strains | 1 | 1993 | 309 | 0.030 |
Why?
|
| Microscopy, Fluorescence | 1 | 2014 | 329 | 0.030 |
Why?
|
| Proteinuria | 1 | 1993 | 108 | 0.030 |
Why?
|
| Survival Rate | 1 | 1998 | 2184 | 0.030 |
Why?
|
| Threonine | 1 | 2013 | 61 | 0.020 |
Why?
|
| Epoprostenol | 1 | 2013 | 45 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2013 | 436 | 0.020 |
Why?
|
| Citrulline | 1 | 1994 | 114 | 0.020 |
Why?
|
| Castration | 1 | 2012 | 28 | 0.020 |
Why?
|
| Glutathione | 1 | 2013 | 200 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2014 | 611 | 0.020 |
Why?
|
| Rats, Inbred Strains | 1 | 1992 | 219 | 0.020 |
Why?
|
| Serine | 1 | 2013 | 166 | 0.020 |
Why?
|
| Embryonic Development | 1 | 1993 | 221 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2000 | 3873 | 0.020 |
Why?
|
| Texas | 1 | 2020 | 3632 | 0.020 |
Why?
|
| Neurons | 1 | 2001 | 2016 | 0.020 |
Why?
|
| Muscle Spindles | 1 | 2010 | 5 | 0.020 |
Why?
|
| Receptors, Purinergic P2X3 | 1 | 2010 | 3 | 0.020 |
Why?
|
| Receptors, Cell Surface | 1 | 1992 | 452 | 0.020 |
Why?
|
| Brain | 1 | 2001 | 3201 | 0.020 |
Why?
|
| Adjuvants, Pharmaceutic | 1 | 2007 | 13 | 0.020 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2014 | 742 | 0.020 |
Why?
|
| Physical Stimulation | 1 | 2007 | 39 | 0.020 |
Why?
|
| Sodium Chloride | 1 | 2007 | 93 | 0.020 |
Why?
|
| Injections, Intramuscular | 1 | 2007 | 196 | 0.020 |
Why?
|
| Hot Temperature | 1 | 2007 | 142 | 0.020 |
Why?
|
| Freund's Adjuvant | 1 | 2006 | 27 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2007 | 448 | 0.020 |
Why?
|
| Keratins | 1 | 2006 | 52 | 0.020 |
Why?
|
| Giant Cells | 1 | 2006 | 35 | 0.020 |
Why?
|
| Afferent Pathways | 1 | 2005 | 16 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2007 | 351 | 0.020 |
Why?
|
| Functional Laterality | 1 | 2006 | 195 | 0.020 |
Why?
|
| Choriocarcinoma | 1 | 2005 | 4 | 0.010 |
Why?
|
| Macrophages | 1 | 2010 | 693 | 0.010 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2005 | 51 | 0.010 |
Why?
|
| Gene Expression Regulation, Bacterial | 1 | 2005 | 173 | 0.010 |
Why?
|
| Uterine Neoplasms | 1 | 2005 | 112 | 0.010 |
Why?
|
| Cytokines | 1 | 2010 | 1366 | 0.010 |
Why?
|
| Receptors, Somatomedin | 2 | 1994 | 24 | 0.010 |
Why?
|
| Oxidative Stress | 2 | 1997 | 799 | 0.010 |
Why?
|
| Cell Division | 2 | 1994 | 744 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 2 | 1994 | 1047 | 0.010 |
Why?
|
| Edetic Acid | 1 | 2000 | 23 | 0.010 |
Why?
|
| Rats, Inbred BN | 1 | 2000 | 16 | 0.010 |
Why?
|
| Molecular Sequence Data | 2 | 1996 | 3778 | 0.010 |
Why?
|
| Calmodulin | 1 | 2000 | 209 | 0.010 |
Why?
|
| Lipid Peroxides | 1 | 1997 | 15 | 0.010 |
Why?
|
| Osteocalcin | 1 | 1997 | 46 | 0.010 |
Why?
|
| Femur | 1 | 1997 | 74 | 0.010 |
Why?
|
| Tibia | 1 | 1997 | 80 | 0.010 |
Why?
|
| Methylprednisolone | 1 | 1997 | 98 | 0.010 |
Why?
|
| Immunochemistry | 1 | 1996 | 24 | 0.010 |
Why?
|
| Lipid Peroxidation | 1 | 1996 | 93 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1996 | 652 | 0.010 |
Why?
|
| Bone Marrow Cells | 1 | 1997 | 263 | 0.010 |
Why?
|
| Diethylamines | 1 | 1995 | 1 | 0.010 |
Why?
|
| Stereoisomerism | 1 | 1995 | 119 | 0.010 |
Why?
|
| Connexin 43 | 1 | 1995 | 34 | 0.010 |
Why?
|
| Molecular Probes | 1 | 1994 | 29 | 0.010 |
Why?
|
| Carbachol | 1 | 1993 | 15 | 0.010 |
Why?
|
| Nifedipine | 1 | 1993 | 22 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 1996 | 2674 | 0.010 |
Why?
|